Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    general medicine

    Hyperviscosity syndrome

    Also known as: HVS, Symptomatic blood hyperviscosity, Hyperviscosity state

    Hyperviscosity syndrome is characterised by increased blood viscosity impeding systemic perfusion, sometimes secondary to excess circulating immunoglobulins in haematological malignancy. Clinical manifestations including visual impairment, neurological deficits, and bleeding constitute medical emergencies requiring urgent hospital assessment. Acupuncture and Chinese herbal medicine do not treat the acute emergency and must not delay haematology care, therapeutic plasma exchange when indicated, or disease-directed therapy. Current evidence, including case reports on Waldenström macroglobulinaemia and myeloma-associated thrombosis, alongside an indirectly relevant hearing-loss case and experimental rat imaging, fails to demonstrate acupuncture or herbal benefit. TCM frameworks for the recovery phase are restricted to managing residual symptoms in medically stable patients following complete medical stabilisation and explicit treating-team clearance.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Attend all scheduled haematology reviews and adhere to monitoring protocols; report any recurrence of symptoms immediately rather than awaiting scheduled appointments.
    • •Adhere strictly to fluid intake volumes prescribed by the medical team, particularly in cases of comorbid renal or cardiac insufficiency; increased oral hydration is not a substitute for clinical management of symptomatic hyperviscosity.
    • •Maintain regular meals and restrict exertion to gentle, individually cleared activity; cease activity and seek medical advice if dizziness, breathlessness, or unusual weakness occurs.
    • •Maintain a comprehensive record of all pharmaceuticals, herbs, and supplements; ensure any new product is cleared by a pharmacist or specialist prior to administration.

    Cautions & Contraindications

    See sources
    • •Suspected or recurrent symptomatic hyperviscosity is a contraindication to proceeding with adjunctive treatment: defer all needling and herbs and arrange urgent medical care. The supplied case supports medical management, not TCM treatment.[]
    • •During myeloma treatment or prescribed thromboprophylaxis, do not stop or alter anticoagulants to enable acupuncture. Review bleeding risk and herb–medicine interactions with the treating team; the supplied review addresses thrombosis, not acupuncture safety.[]
    • •Severe anaemia, active infection or unstable cancer-treatment complications require medical review before any recovery-phase adjunct. Do not infer safety from the Waldenström case, which included severe anaemia and subsequent infection.[]

    When to reassess or seek care again

    See sources

    Emergency symptoms require immediate referral, not a trial of adjunctive care. If a fully stabilised patient receives specialist-cleared recovery support, review within 1–2 weeks using fatigue severity on a 0–10 scale, meal intake, sleep duration and daily activity tolerance. Continue specialist-directed blood monitoring; symptom improvement does not demonstrate reduced viscosity. Stop adjunctive care and urgently refer for recurrent visual or neurological symptoms, bleeding, fever, new breathlessness or functional decline. Reconsider continued adjunctive treatment if no meaningful functional benefit within 2–4 weeks.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Experimental and therapeutic medicine · 2026
    2. Cancer management and research · 2025
    3. International journal of women's health · 2025
    4. Frontiers in bioengineering and biotechnology · 2023
    5. Cochrane Database of Systematic Reviews · 2015

      Systematic review supporting PC6 stimulation for postoperative nausea and vomiting.

    6. JAMA Surgery · 2023

      Randomised trial including ST36 for postoperative gastrointestinal recovery.

    7. World Health Organization · 2008

      Standard point locations used for the adjunctive points listed.

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.